Skye Bioscience Inc.(US:SKYE) Newsfile·2025-12-06 22:35Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1: Class Action Details - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [4]. - The lawsuit alleges that Skye's management made materially false and misleading statements regarding the effectiveness and prospects of its product, nimacimab, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [5].